Scalper1 News
Valeant Pharmaceuticals International (VRX) confirmed Sunday that it will buy smaller rival Salix for $158 a share, with a total enterprise value of $14.5 billion. Both companies’ boards have approved the all-cash offer. They expect the merger to yield more than $500 million in cost savings, and boost EPS by 20% in 2016. Salix Pharmaceuticals (SLXP) shares rose 4.7% on the stock market Friday to 157.85, amid widespread reports that a deal was Scalper1 News
Scalper1 News